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Rational therapy requires accurate diagnosis. When we apply
this precept to anxiety a fundamental question arises. Is anxiety
an illness in terms of the now berated medical model which holds
that an illness has a cause, a natural history, and hopefully a cure?
Or is anxiety a basic aspect of the
human condition, an innate pattern
of response which becomes pathological when stress, induced by
physiologic and social forces, is
magnified out of proportion to the
original stimulus? If the latter is
true, then stress and social interactions are the causative factors,
the anxiety only a reaction. Logically then, the condition of anxiety can be modified by alleviating stress or changing the social
environment. Although there is no
definitive answer to this major
question concerning the nature of
anxiety, we would like to present
briefly some of the present knowledge about it.
In 1921, Freud stated: "We call
it [anxiety] an affective state, although we are also ignorant of
what an affect is." He discussed
three components of anxiety: (1)
the specific feeling of unpleasure,
(2) acts of discharge (autonomic
and endocrine functions), and ( 3)
perceptions of these acts. Although
more knowledge of biochemical
and neurophysiologic mechanisms
has accumulated since Freud made
this observation little more is
known about anxiety. Engel
( 1962) proposed that anxiety is
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the earlier of two basic biological
patterns of which depression-withdrawal is second. He says that
anxiety "includes a variety of active modes of coping with stress
which are designated the fiight-fight
patterns to indicate corresponding
behavioral aspects (Cannon, 1939).
These involve not only the biochemical and physiological preparations for flight or fight but also internal changes anticipating bodily
injury." The psychophysiology of
anxiety is neuroendocrinological,
including activity of the limbic system and the hypothalamus, which
leads to activation of the pituitaryadrenal cortical system and facilitates a wide range of metabolic
processes involved in the long-term
responses to injury (Engel, 1953;
Ingle, 1952; Selye; 1960).
Grinker (1956) characterized
the clinical manifestations of anxiety quantitatively. Mild anxiety
is consonant with alertness or vigilance; it may be automatic, and the
patient has little psychical or physical awareness of his anxiety.
Greater quantities are manifested
as episodes of recognized apprehension with physical symptoms.
Thirdly, free anxiety, which may
be episodic or continuous, is obviously neurotic. As the anxiety
becomes more severe, disorganization of function occurs.
These are the fundamental
psychiatric concepts. For the sake
of completeness we should include
that Berger (1962) propounds a
strictly organic point of view when
he says that anxiety is a "disease
of the brain." In contrast, others
see anxiety as a patterned re101
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sponse; neurotic symptoms are
learned faulty patterns of behavior
(Hall and Lindzey, 1957). ' Further, many theorists believe that
anxiety is a constructive force,
which not only acts as a danger
signal to protect the organism, but
also accounts for motivation and
monitors behavior.
In medicine, psychosomaticists
hold that excessive or sustained
anxiety produces disturbances of
bodily functions or structures
which in turn result in organic illness. Physicians find that anxiety is
a contributing factor, a correlate,
or a result of many disease states.
They are concerned with treating
patients with acute, distressing "anxiety" attacks and those with high
levels of chronic anxiety who are
difficult to work with because of
their general nervousness, irritability, fright, and erratic behavior.

Goodman and Gilman ( 1965a) :
"obviously neither drugs nor other
somatic treatment can give the
insight to the patient that can be
achieved by psychotherapy."
Psychotherapy

We like Appel's definition of
psychotherapy as quoted by Rickels (1964) : "helping people to
handle their feelings, motivations,
and behavior more appropriately."
And we should remember that
psychotherapy is one of the oldest
medical skills. The essence of
psychotherapy is communication,
and achieving the therapeutic dialogue is dependent on the relationship between the patient and the
physician~

Despite our difficulties in understanding the nature of anxiety,
awareness of it is increasing in the
Western world (Andresen, 1963;
Finn and Rusten, 1966; Rennie,
1948). Adams and Hope ( 1962)
observe: "As a clinical syndrome,
the anxiety state outranks all other
problems in general medicine."
Our studies (Schwab et al., 1966a,
b, and c) with medical inpatients
showed that 20 % to 27 % of them
had severe anxiety. These data are
in accord with Cattell and Scheier's
statement ( 1961 ) : "Epidemiological estimates vary . . . [but] a conservative consensus estimate would
probably place 20% of the American population as needing treatment for disorders in which anxiety plays a prominent role."

By listening, the therapist tries
to obtain understanding, not necessarily agreement but rather comprehension. Either sympathetic
agreement or antagonistic disagreement may produce distortions and
solidify the neurotic organization.
Thus, the task of the therapist is,
in Wahl's words (1962) " . . . to
convert apprehension to comprehension."
From awareness of his problems comes clarification; the patient is better able to make more
appropriate decisions about his
life. Other fundamentals of psychotherapy are the educative and the
manipulative, deriving from increased knowledge of self and environment.
Just as communication is the
essence of psychotherapy, self esteem is the fulcrum on which success balances. Only with increased
self esteem can the patient order
his world and create healthful relationships with it.

Treatment

Medication

The effective treatment of anxious patients hinges on the combined benefits of psychotherapy
and medications. The limitations
of psychotherapy are well known,
and the limitations of drug therapy
have been aptly expressed by

Medication is the second component of treatment. When tranquilizers were first introduced, it
was feared that they would render
the patient too comfortahle for
psychotherapy. Obviously, this fear
has not been realized. Available
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medications do not purge anxiety,
but they can reduce it to manageable proportions, thereby improving personal relationships, and
forestalling ego disorganization
and psychosis.
Guidelines

To obtain maximal advantages
in the use of drugs, the therapist
must adhere to certain principles.
1. Little is known about their
pharmacologic action. Most of
these agents act as weak sedatives.
The barbiturates, of course, are depressants of the recticular formation in the brain stem. The action
of meprobamate is quite similar;
although no specific site of action
has been identified. Hendley et al.
(1954) indicated, however, that it
produces some thalamic synchronization, and others have observed
slow wave activity in the basal
ganglia and limbic system. It may
interfere with centrally mediated
autonomic responses. Indirectly, by
affecting cond~ction in the limbic
system, it appears to depress the
recticular formation.
According to Goodman and
Gilman (1965b), the effects of
chlordiazepoxide (Librium) and
the related compounds diazepam
(Valium) and oxazepam (Serax)
are more ubiquitous than those of
meprobamate and the barbiturates.
Chlordiazepoxide has a central action, possible peripheral actions,
and a definite sedative effect intermediate in potency between
meprobamate and chlorpromazine.
Like barbiturates and meprobamate, in experimental animals it
blocks both conditioned and unconditioned avoidance responses.
The phenothiazines (Thorazine,
Mellaril, Stelazine) appear to produce changes at many levels: the
EEG is characteristic of drowsiness; arousal is diminished; there
are some effects upon the limbic
system and the basal ganglia; and
conditioned avoidance responses
are blocked without affecting the
unconditioned responses. Jarvik
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( 1965) states that there are "several disparate views concerning
the sedative action of chlorpromazine and its effects on the recticular system." Various investigators
contend that it depresses, that it
has a biphasic action, or even that
it is stimulating. Through its depressive action on the hypothalamus, it has strong adrenergic and
weak cholinergic blocking effects
on the autonomic nervous system,
and it acts on the endocrine system to reduce urinary gonadotropins, suppress estrous cycles,
interfere with growth, induce lactation, and decrease secretion of
ACTH.
2. The dosage must be carefully individualized. For example,
some patients respond to 1200 mg
of meprobamate per day, whereas
others receive little benefit unless
that is doubled. This is even more
true of the phenothiazines; some
patients improve on 100 mg of
chlorpromazine in 24 hours,
whereas others require many times
that amount.
3. They provide only symptomatic relief by damping reactions
and quieting inner turbulence.
Thus they are only adjuncts.
4. They are not remedies for
psychosocial distress. Too often
tranquilizers are prescribed for the
treatment of sociocultural dilemmas; obviously when used for these
purposes the results will be poor.
5. Negative effects occur. Some
patients react poorly to one or all
of the antianxiety agents. Paradoxical reactions, to say nothing of
side effects, are reported for meprobamate, the
benzodiazepine
compounds (such as Librium), and
the phenothiazines.
6. Knowledge of the patient's
personality is essential. DiMascio
and Klerman ( 1960) concur with
the almost universal recognition
that the personality of the subject
and his psychophysiologic state are
important modifiers of drug action.
Many anxious patients cannot tolerate a slowed-down feeling; it results in clinical depression for

some and a loss of required motor
activity for others. Importantly,
Rickels ( 1964) has described the
effects of the barbiturates as producing more improvement in lower
socioeconomic patients who have
low drive levels, low ambition,
highly compliant behavior, and a
strong passive-dependent character
makeup. In the more intelligent,
less dependent, less compliant and
socioeconomically higher patient,
the barbiturates are less well tolerated, producing more sedation
and less improvement.
7. The physician should restrict
his use of the countless sedatives
and tranquilizers available to only
a few, so that he can become familiar with their indications, side
effects, and contraindications.
Sainz ( 1964) states : "The rate at
which new psychopharmacologic
agents appear and old ones disappear attests only to their relative
ineffectiveness." We advocate that
one should switch to a new drug
only when it has been proved
demonstrably superior. Among the
phenothiazines, chlorpromazine is
still the standard against which
others are measured. And, meprobamate and chlordiazepoxide have
been used for so many years with
so many patients that their effects
and side effects are well known.
Clinical States
In practice, patients are seen
with various anxiety states, which
can be conceptualized on two dimensions: the first is the continuum from conscious to unconscious awareness of causes and
dynamics; and the second is severity, ranging from the stress reaction, which may be mild, to the
extreme anxiety manifested by the
schizophrenic patient who is undergoing ego disorganization.
( 1) The acute stress reaction is
evidenced clinically by: agitation,
restlessness, autonomic symptoms,
insomnia, and visceral dysfunctions. Conscious elements are predominant; i.e., the patient is aware

of his tension and is able to describe its causes and effects. The
severity is commensurate with the
degree of trouble the patient is encountering. The ordinary dilemmas
of human existence, i.e., problems
of work and family, are the most
common causes.
Psychotherapy should be directed toward helping the patient
resolve the environmental stress or
removing him from it. Medications
may be necessary, but in these instances they should be given for
only a short time because their
chronic use may produce just
enough relief that the patient, instead of seeking resolution, remains helplessly and symptomatically caught in a stressful situation.
Barbiturates, either sodium amytal
or butabarbital (30 mg three or
four times a day), are useful.
Sometimes adequate sedation at
bedtime suffices. Of course, barbiturates have drawbacks: sedation, addictive properties, and possible use for suicide. Meprobamate
( 400 to 800 mg three times a day)
is obviously preferable when there
is any risk of suicide.
(2) Although acute anxiety attacks usually appear as discrete
clinical syndromes, the patient is
relatively unaware of the precipitating events and the dynamics. He
displays overt apprehension and
the symptoms of autonomic nervous system imbalance. He complains of severe dread, a fear that
he is dying, or that he is affiicted
by a terrifying condition. The
physical symptoms include headache, an inability to concentrate,
rapid heartbeat, shortness of
breath, gastrointestinal distress, bizarre sensations, and generalized
motor hyperactivity. Also, he may
be hyperventilating, complaining of
tingling of the extremities and
sharp twitches of pain in the chest,
and showing signs such as pallor,
profuse sweating, and muscle
spasms.
Clarification of the patient's
physical status usually terminates
the acute attack, but seldom pre103
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vents its recurrence. When these
patients are first seen the physician
should explore possible causes incisively. If the anxious condition
becomes chronic, the patient focuses on his symptoms so completely that his awareness of other
stresses diminishes and valuable information cannot be obtained. Because these patients are suffering
and frightened, they accept direct
questioning about the quality of
their interpersonal relationships,
stresses at home and work, sexual
activities, basic fears regarding
adequacy, etc. Psychotherapy is essential because the patient is unaware of the dynamics and usually
of the precipitating events.
Intravenous sodium amytal (200
to 500 mg) quickly relieves the
acute attack. Meprobamate ( 400 to
800 mg three times a day) or
chlordiazepoxide (Librium) (10
to 25 mg three times a day) alleviates the anxious condition but
does not protect the patient from
recurrence. Therefore, we recommend both intensive psychotherapy
and medications. Side effects of
the antianxiety agents (meprobamate and chlordiazepoxide) include withdrawal reactions, paradoxical reactions, and allergic conditions.
(3) Chronic anxiety states are
persistent, the causes obscure, and
the manifestations multifarious.
Engel (1962) says: "The somatic
symptomatology and the physiologic changes associated with anxiety set in motion a vicious cycle
-the patient begins to fear the
onset of the next acute anxiety attack and his perception of somatic
symptoms reinforces this signal of
danger." Repeated acute attacks
thus lead to the chronic condition;
the baseline level of anxiety between attacks is raised.
Chronic anxiety is evidenced by
the patient's worried, tense appearance which is accentuated as
the day goes on and the stresses
and strains of activity take their
toll. Although the anxious patient
has difficulty going to sleep, he
104

feels better in the morning. In contrast, the depressed patient is generally more apathetic in the morning and brighter in the evening.
Morbidly anxious patients are preoccupied with their mental and
physical status, speaking freely of
their symptoms, and betraying
their agitation by trembling and
tension. Although they describe
symptoms easily, they do not know
what is happening to them. If unchecked, the condition becomes
progressively more severe and
panic states develop.
Psychiatric referral is recommended. Because the condition is
both severe and chronic, medications are usually needed to help
the patient work with a psychiatrist. If the patient displays muscle
tension and agitation and if his
ego strength is reasonably good,
meprobamate is preferred. For the
patient who appears more psychiatrically ill, obsessive, and has diffuse complaints, chlordiazepoxide
(Librium) is usually more effective. For the even more clinically
ill patient who will require medication over a period of months,
phenothiazine compounds should
be used. We start with 25 mg of
chlorpromazine (Thorazine) or
thioridazine (Mellaril) four times
a day, check for hypotensive reactions, and then increase the dosage by 50 to 100 mg every few
days until the patient notices some
relief or side effects apear. The
most common side effects are dyskinesias, particularly parkinsonism and akathisia. Dystonia is seen
only occasionally. In recent years
the reports of jaundice and agranulocytosis have diminshed greatly.
Hyperpigmentation and photosensitivity as well as pigmentation of
the cornea and lens have been reported (Redlich and Freedman,
1966). Recently Hollister ( 1966)
noted that some patients taking
chlorpromazine for many years
were found at post-mortem examination to have coronary artery
changes, but this has not yet been
confirmed.

( 4) Anxiety is also evidenced
clinically by neurotic behavior and
attitudes, and a host of characterologic defenses, particularly by patients who have little awareness of
their anxiety. Interpersonal relationships suffer. These manifestations of anxiety appear so intangible that the physician is reluctant
to refer the patient for psychiatric
consultation until more obvious
difficulties appear. The neurotic
behavior includes emotional !ability, erratic and inconsistent attitudes, and impaired communication
--especially between patient and
physician. This may be so great
that the physician and his patient
are unable to agree about the
severity of the illness or the necessity for particular types of treatment.
We found that highly anxious
medical patients hold distorted
views of the severity of their illnesses, maintain negative feelings
(even flagrant dislike) for hospitalization, and distrust their physicians. They display manifold characterologic defenses: irritability,
suspicion, lack of cooperation, and
passive-aggressive activities
(Schwab et al., 1966a).
When anxiety is expressed
through these defenses, the severity
is variable; the defenses become an
integral part of the character structure so that the person lives with
the reputation of being troublesome. But more severe anxiety
states develop when he is stressed
by medical illness or one of life's
catastrophes.
In these patients medications
have little value; the defenses bind
the anxiety, and the patients consider their personality symptoms to
be ego-syntonic. Psychotherapy also
has limited effectiveness until the
patient's interpersonal difficulties
multiply.
(5) Overwhelming anxiety is a
conspicuous symptom of schizophrenic reactions, particularly the
acute undifferentiated type. These
patients show many of the classic
signs of schizophrenia: they are
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vague, their thinking is autistic and
highly personalized, ambivalence
and indecisiveness are obvious,
their affect is one of fright and
suspicion, and of course they may
be hallucinatory or delusional.
They are not aware of the sources
of their anxiety, or their description is so incoherent that they cannot communicate with others. In
the milder forms, misdiagnosis is
common. For example, Lynn
(1964) fol.ind that of 133 patients
referred for psychiatric consultations to the Indiana University
Medical Center, 34 schizophrenic
patients had been either misdiagnosed or inadequately treated.
The schizophrenic patients with
less severe disorders respond well
to psychotherapy that emphasizes
specificity, concreteness, and current realities. Phenothiazines are
the only medications which are
really beneficial. Ambulatory schizophrenic patients require 200 to
500 mg of chlorpromazine (Thorazine) per day for many months.
When the medication is discontinued it should be reduced gradually over a period of months.
(6) Newer concepts of mental
illness now recognize admixtures of
anxiety and depression. Once they
were rigidly differentiated as entities, but now we know a patient
may appear at any point on the
continuum ranging from so-called
"pure" anxiety, through complex
reactions which manifest both anxious and depressive elements concurrently, to the more classical, obvious, retarded depressive state.
Many of these patients respond
to the newer antidepressant medications, particularly those which
exert some phenothiazine-like action. Amitriptyline (Elavil) (10 to
25 mg three or four times a day)
or nortriptyline hydrochloride
(Aventyl) (20 to 100 mg daily)
are recommended. Several British
investigators (Sargant, 1962; Sargant and Dally, 1962) have reported on the successful use of
MAO inhibitors for the treatment
of patients showing anxiety as a

prominent feature of their illness;
however, we have had no experience with them in the treatment
of these patients. These various antidepressants should not be used in
combination and can be used in
tandem only if there is a 7 to 14
day drug-free interval between
them.
It is impossible to generalize
about psychotherapy for these patients. Some are benefited; many
are not. Each case must be individualized.
Conclusions About Drug

Therapy
Evaluating the tranquilizing
agents is complicated for a number
of reasons; the literature is filled
with inconsistencies.
First, the end result is often a
non-specific, "feeling better," which
defies quantification.
Second, selected patient samples
are used for much of the research.
In this respect, Rickels (1964)
found that conscious and unconscious attitudes toward physicians
differ greatly in lower social class
patients visiting a medical clinic,
as compared with middle social
class patients visiting a psychiatric
clinic. Moreover, the physician, usually a member of the middle or
upper social class, is better able
to understand and treat patients
with similar backgrounds and aspirations than patients from the lower
social classes. Yet, this latter group
is frequently in even greater need
of help.
Third, drug response varies with
the motivation of the subject (DiMascio and Klerman, 1960). Financial remuneration, counterphobic defenses, and wishes to
establish contact with psychiatric
personnel motivate subjects who
take part in drug studies.
Finally, most clinical trials are
conducted for only four to six
weeks. We have found that many
anxious patients will improve on
any medication during the first few
weeks. Yet many reports of the ef-

ficacy of these medications are derived from such brief studies.
Notwithstanding these difficulties, when properly used, the psychopharmacologic agents have benefited many patients. And, just as
importantly, the use of our relatively crude compounds of the
1960's lends hope that we are just
on the threshold of a biochemical
and psychopharmacologic era in
which our knowledge of the physiology of the brain will become exact, the mechanics underlying
mental illness will be revealed, and
definitive drugs for treatment will
be found.
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